Targeted Magnetic Resonance Imaging Contrast Agents

  • E. Edmund Kim


Magnetic resonance (MR) contrast agents have been used to improve detection of lesions (better contrast-to-noise ratio) or to improve their characterization by changing tissue signal intensity. The more specific the accumulation of a contrast agent within the target tissue, the better the lesion-to-tissue contrast. Ideally, the target should be an organ of sufficient size with a large number of specific binding sites and also have a high blood flow. Target-specific molecules are called vectors, and “the carrier” means a compound-containing vector. Typical carrier systems include antibodies, proteins, peptides, polysaccharides, cells, and liposomes.


Contrast Agent Magnetic Resonance Angiography Magn Reson Image Superparamagnetic Iron Oxide Magnetic Resonance Image Contrast Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wang SC, Wikström MG, White DL, et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent. Radiology 1990;175:483–488.PubMedGoogle Scholar
  2. 2.
    Voxler VS, Clement O, Schmitt-Willich H, et al. Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns. J Magn Reson Imaging 1994;4:381–388.CrossRefGoogle Scholar
  3. 3.
    Brasch RC New directions in the development of MR imaging contrast media. Radiology 1992; 183:1–11.PubMedGoogle Scholar
  4. 4.
    Leander P. Liver-specific contrast media for MRI and CT experimental studies. Acta Radiol Suppl 1995;396:1–36.PubMedGoogle Scholar
  5. 5.
    Weissleder R, Papisov M. Pharmaceutical iron oxides for MRI. J Magn Reson Imaging 1992; 4:1–6.Google Scholar
  6. 6.
    Shen T, Weissleder R, Papisov M, et al. Mono-crystalline iron oxide nanocompounds (MION). Magn Reson Med 1993;29:599–604.PubMedCrossRefGoogle Scholar
  7. 7.
    Orang-Khadivi K, Pierce BL, Ollom CM, et al. New magnetic resonance imaging techniques for the detection of breast cancer. Breast Cancer Res Treat 1994;32:119–135.PubMedCrossRefGoogle Scholar
  8. 8.
    Stenzel-Johnson PR, Yelton D, Bajorath J, et al. Identification of residues in the monoclonal antibody L6 important for binding to its tumor antigen. Biochemistry 1994;33:14400–14406.PubMedCrossRefGoogle Scholar
  9. 9.
    Weissleder R, Lee AS, Khaw BA. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infract. Radiology 1991;181: 245–249.PubMedGoogle Scholar
  10. 10.
    Schaffer BK, Linder C, Papisov M, et al. MION-ASF: biokinetics of an MR receptor agent. Magn Reson Imaging 1993;11:411–417.PubMedCrossRefGoogle Scholar
  11. 11.
    Reimer P, Weissleder R, Wittenberg J, et al. Receptor-directed contrast agents for MRI. Radiology 1992;182:565–569.PubMedGoogle Scholar
  12. 12.
    van Everdingen KJ, Enochs WS, Bhide PG, et al. Determinants of in vivo MRI of slow axonal transport. Radiology 1994;193:485–591.PubMedGoogle Scholar
  13. 13.
    Reimer P, Weissleder R, Shen T, et al. Pancreatic receptors: initial feasibility studies with a target contrast agent for MRI. Radiology 1994;193: 527–531.PubMedGoogle Scholar
  14. 14.
    Weissleder R, Papisov M. Pharmaceutical oxides for MRI. Rev Magn Reson Med 1992;4:1–20.Google Scholar
  15. 15.
    Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography. Radiology 1994;191:225–230.PubMedGoogle Scholar
  16. 16.
    Vassallo P, Matei C, Heston WD, et al. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology 1994;193:501–506.PubMedGoogle Scholar
  17. 17.
    Harika L, Weissleder R, Poss K, et al. MR lymphography with a lymphotropic Tl-type MR contrast agent: Gd-DTPA-PGM. Magn Reson Med 1995;33:88–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Reimer P, Weissleder R, Brady TJ, et al. Experimental hepatocellular carcinoma: MR receptor imaging. Radiology 1991;180:641–645.PubMedGoogle Scholar
  19. 19.
    Weissleder R, Wang YM, Papisov M, et al. Polymeric contrast agents for MRI of adrenal glands. J Magn Reson Imaging 1993;3:93–97.PubMedCrossRefGoogle Scholar
  20. 20.
    Mühler A, Platzek J, Radüchel B, et al. Characterization of a Gd-cholesterol derivative as an organ specific contrast agent of adrenal imaging. J Magn Reson Imaging 1995;5:7–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–1887.PubMedCrossRefGoogle Scholar
  22. 22.
    Niesman MR, Bacic GG, Wright SM, et al. Liposome encapsulated MnCl2 as a liver specific contrast agent for MRI. Invest Radiol 1990;25: 545–551.PubMedCrossRefGoogle Scholar
  23. 23.
    Yeh T, Zhang W, Ilstad ST, et al. Intracellular labeling of T-cells with superparamagnetic contrast agents. Magn Reson Med 1993;30:617–625.PubMedCrossRefGoogle Scholar
  24. 24.
    Bulte JWM, Ma LD, Magin RL, et al. Selective MRI of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles. Magn Reson Med 1993;29:32–37.PubMedCrossRefGoogle Scholar
  25. 25.
    Mahfouz A-E, Hamm B. Contrast agents. MRI Clin North Am 1997;5:223–240.Google Scholar
  26. 26.
    Petersein J, Saini S, Weissleder R. Iron oxide-based reticuloendothelial contrast agents for MRI. MRI Clin North Am 1996;4:53–60.Google Scholar
  27. 27.
    Weissleder R, Reimer P, Lee AS, et al. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR 1990;155:1161–1167.PubMedCrossRefGoogle Scholar
  28. 28.
    Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MRI. Radiology 1990;175:489–493.PubMedGoogle Scholar
  29. 29.
    Ros PR, Freeny PC, Harms SE, et al. Hepatic MRI with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481–488.PubMedGoogle Scholar
  30. 30.
    Kopp AF, Laniado M, Dammann F, et al. MRI of the liver with Resovist: safety, efficacy and pharmacodynamic properties. Radiology 1997;204: 749–756.PubMedGoogle Scholar
  31. 31.
    Shamsi K, Balzer T, Saini S, et al. Superparamagnetic iron oxide particles (SH U 555A): evaluation of efficacy in three doses for hepatic MRI. Radiology 1998;206:365–371.PubMedGoogle Scholar
  32. 32.
    Vogl TJ, Hammerstingl R, Schwartz W, et al. Superparamagnetic iron oxide-enhanced versus Gd-enhanced MRI for differential diagnosis of focal liver lesions. Radiology 1996;198:881–887.PubMedGoogle Scholar
  33. 33.
    Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide (USPIO): an intravenous contrast agent for assessing lymph nodes with MRI. Radiology 1990;175:494–498.PubMedGoogle Scholar
  34. 34.
    Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995;164:1147–1152.PubMedCrossRefGoogle Scholar
  35. 35.
    Mergo PJ, Helmberger T, Nicolas AL Ring enhancement in ultrasmall superparamagnetic iron oxide MRI: a potential new sign for characterization of liver lesions. AJR 1996;166:379–384.PubMedCrossRefGoogle Scholar
  36. 36.
    Mitchell DG, Outwater EK, Matteucci T, et al. Adrenal gland enhancement at MRI with Mn-DPDP. Radiology 1995;194:783–787.PubMedGoogle Scholar
  37. 37.
    Wang C, Ahlstrom H, Eriksson B, et al. Uptake of mangafodipir trisodium in liver metastases from endocrine tumors. J Magn Reson Imaging 1998;8:682–686.PubMedCrossRefGoogle Scholar
  38. 38.
    Rofsky NM, Weinref JC, Bernardin ME, et al. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MRI. Radiology 1993;188: 53–59.PubMedGoogle Scholar
  39. 39.
    Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MRI with mangafodipir trisodium (Mn-DPDP). Radiology 1996;200:69–77.PubMedGoogle Scholar
  40. 40.
    Oksendal AN, Hals PA. Biodistribution and toxicity of MRI contrast media. J Magn Reson Imaging 1998;3:157–165.CrossRefGoogle Scholar
  41. 41.
    Runge VM. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Asst Tomogr 1998; 22:643–650.CrossRefGoogle Scholar
  42. 42.
    Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998;207:529–538.PubMedGoogle Scholar
  43. 43.
    Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998;207:539–544.PubMedGoogle Scholar
  44. 44.
    Schmiedl U, Sievers RE, Brasch RC, et al. Acute myocardial ischemia and reperfusion: MRI with albumin-Gd-DTPA. Radiology 1989;170:351–356.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • E. Edmund Kim

There are no affiliations available

Personalised recommendations